Abstract: A new oral IR formulation in solid form for a low molecular weight thrombin inhibitor having pH dependant dissolution, characterized in that the formulation comprises a filler or a combination of fillers having disintegrant properties in an amount higher than 35% w/w of the formulation.
Type:
Grant
Filed:
November 30, 1999
Date of Patent:
February 18, 2003
Assignee:
AstraZeneca AB
Inventors:
Sigbrit Forsman, Christer Karlsson, Magnus Karlsson
Abstract: This invention describes non-staining, pharmaceutically useful compositions of ionic complexes made between the cationic polymer chitosan or its derivatives and the small anionic iodine-iodide complex (ICIC's). Unlike previously disclosed ion transfer chitosan iodine complexes, ICIC's were found to possess dramatically higher viscosity than those of each ingredient separately, and instantly form a gel structure that is easily dispersible upon shaking. In addition to their antiseptic power, ICIC's showed better skin biocompatibility than povidone iodine and effectively promoted wound healing.
Abstract: The invention provides novel micro-cluster liquids and methods for manufacturing and using them. The micro-cluster liquids comprise fractionized or micro-cluster liquids, (e.g. water, such as oxygenated micro-cluster water). The methods comprise causing cavitation of a liquid to form cavitation bubbles under a first pressure followed by depressurization to a second pressure to cause implosion and explosion of the cavitation bubbles such that acoustical energy shockwaves are created. The micro-cluster water (e.g., oxygenated micro-cluster water) is used to deliver hydration, oxygenation, or agents, such as nutritional agents or medications, and increasing overall cellular performance and exchanging liquids in the cell within minutes of consumption.
Type:
Grant
Filed:
October 26, 2000
Date of Patent:
February 18, 2003
Assignee:
Bio-Hydration Research Lab, Inc.
Inventors:
Michael A. Holloway, William D. Holloway, Jr.
Abstract: A gelled composition was provided by adding a gelling component to a carrier for adsorption. Not only was the taste of the carrier for adsorption significantly reduced in this composition, but the dosage was also decreased so that the composition could be easily taken by a patient.
Abstract: The invention relates to a bioactive implant comprising a substrate coated with a polymer layer with reactive functions, and a bioactive substance fixed on the implant by means of said reactive functions to enable progressive release on the implant site.
Such implants are useful in the field of cardiology for example to prevent restenosis resulting from the fitting of stents in the coronary arteries.
Type:
Grant
Filed:
May 16, 2001
Date of Patent:
February 11, 2003
Assignees:
Commissariat a L'Energie Atomique, Institut National de la Sante et de la Recherche
Medicale, Kerckhoff-Klinik GmbH
Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.
Type:
Grant
Filed:
July 9, 2001
Date of Patent:
February 11, 2003
Assignee:
GelTex Pharmaceuticals, Inc.
Inventors:
Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
Abstract: The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.
Type:
Grant
Filed:
November 28, 2000
Date of Patent:
February 11, 2003
Assignee:
GelTex Pharmaceuticals, Inc.
Inventors:
Caroline Isabelle Bacon Kurtz, Richard Fitzpatrick
Abstract: This invention relates to bioenhanced formulations comprising eprosartan or eprosartan mesylate in the amorphous form, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
Abstract: This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.
Type:
Grant
Filed:
July 12, 2000
Date of Patent:
February 4, 2003
Assignee:
Schering-Plough Veterinary Corporation
Inventors:
Rong Gao, Zezhi Jesse Shao, Allan Chor-Lun Fan, Leonore Catherine Witchey-Lakshmanan, Daniel Charles Stewart
Abstract: Polysaccaride polymers are employed in various medical applications. For example, chitosan—arabinogalactan and polysaccharide amine polymers are disclosed. The polymers can be used to prevent wound adhesion, to provide scaffolds for tissue transplantation and carriers for cell culture.
Abstract: PEG and related polymer derivatives having weak, hydrolytically unstable linkages near the reactive end of the polymer are provided for conjugation to drugs, including proteins, enzymes, small molecules, and others. These derivatives provide a sufficient circulation period for a drug-PEG conjugate and then for hydrolytic breakdown of the conjugate and release of the bound molecule. In some cases, drugs that previously had reduced activity when permanently coupled to PEG can have therapeutically suitable activity when coupled to a degradable PEG in accordance with the invention. The PEG of the invention can be used to impart water solubility, size, slow rate of kidney clearance, and reduced immunogenicity to the conjugate. Controlled hydrolytic release of the bound molecule in the aqueous environment can then enhance the drug delivery system.
Abstract: Compositions useful for long-lasting pain relief from mucosal damage, such as mucosal inflamation, abrasions, ulcerations, lesions, trauma and incisions, without significant systemic absorption. The compositions of the invention are particularly suitable for application to the mucous membrane of the nasal cavity and buccal cavity. To relieve pain, the compositions or the invention are topically applied directly to the affected area.
Type:
Grant
Filed:
June 17, 2002
Date of Patent:
January 21, 2003
Assignee:
EpiCept Corporation
Inventors:
Robert O. Williams, Feng Zhang, John J. Koleng, Gavril W. Pasternak, Yuri A. Kolesnikov
Abstract: In accordance with the present invention, there are provided composition and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.
Abstract: The present invention provides methods and compositions for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of microorganisms including bacteria, bacterial spores, fungi, fungal spores and enveloped viruses.
Type:
Grant
Filed:
April 28, 2000
Date of Patent:
January 14, 2003
Assignee:
Regents of the University of Michigan
Inventors:
James R. Baker, Jr., Tarek Hamouda, Amy Shih, Andrzej Myc
Abstract: A controlled release system for multiphasic, in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time. The controlled release system can comprise a plurality of botulinum toxin incorporating polymeric microspheres.
Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one molecular hook, and at least one linker.
Type:
Grant
Filed:
July 14, 2000
Date of Patent:
January 14, 2003
Assignee:
General Electric Company
Inventors:
Matthew David Butts, Susan Adams Nye, Christopher Michael Byrne
Abstract: The present invention covers pourable liquid vehicles that can be combined with compositions, materials and substances. Among the benefits of such pourable liquid vehicles is the compositions are retained on the moistened surface for a period of time sufficient to allow compositions, materials and substances to act on said surface, resisting erosion or run-off from additional moisture being applied. Such pourable liquid vehicles have a number of utilities including but not limited to cleaning and treating surfaces of objects as well as biological or living organisms, including living creatures.
Type:
Grant
Filed:
September 11, 2000
Date of Patent:
January 7, 2003
Assignee:
The Procter & Gamble Company
Inventors:
Douglas Joseph Dobrozsi, Jerry William Hayes, II, Bjorn Olof Lindman, Rouja Hristova Ivanova, Paschalis Alexandridis
Abstract: The present invention relates to the preparation of orally administrable granules of hexahydropyrazine derivatives by mixing the active compound in the presence of suitable solvents with hydrophobic carriers, if appropriate in the presence of auxiliaries, and converting the resulting mixture, if appropriate, into other ready-to-use forms.
Abstract: The present invention is directed to a stable nitroglycerin containing pharmaceutical composition, preferably a tablet which is prepared by direct compression technology. The formulation closely replicates the properties of nitroglycerin molded sublingual tablets (e.g. adequate disintegration and sublingual absorption), while reducing the problems experienced with compressed tablets (e.g. friability and weight variations). The stable tablets are characterized by a decreased migration of nitroglycerin, decreased potency loss, excellent content uniformity when stored. The preferred combination of components are: nitroglycerin/lactose dilution, hydrous lactose, glyceril monostearate, fumed silica, pregelantinized starch and calcium stearate. The preferred process employs direct compression technology to yield composition showing adequate disintegration, bioavailability and improved stability.
Abstract: A cosmetic composition comprising titanium oxide coated with one or both of silica and alumina or zinc oxide coated with one or both of silica and alumina, and a thickening polymer having a carboxyl group in the side chain, preferably a carboxyvinyl polymer, wherein when 10% by mass of silica- and/or alumina-coated titanium oxide or silica- and/or alumina-coated zinc oxide is dispersed in an aqueous solution containing 0.133% by mass of a carboxyvinyl polymer, the viscosity after the passing of 100 hours is 50% or more of the initial viscosity. A cosmetic composition comprising titanium oxide coated with one or both silica and alumina or zinc oxide coated with one or both of silica and alumina, and a thickening polymer having a carboxyl group in the side chain of the invention, can maintain emulsion stability by thickening of polymer for a long period of time and can be widely and suitably used for ultraviolet shielding cosmetic materials or the like having preparation form stability.